Clinical Trials
42 trialsA Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
EV-309
Astellas Pharma Inc
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
P300
Pathos AI, Inc.
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
STRIKE-001
K36 Therapeutics, Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
DETERMINE
Cancer Research UK
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
TURANDORELA
The Netherlands Cancer Institute
START-001
Marengo Therapeutics, Inc.
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
PROter
Advanced Accelerator Applications
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Promontory Therapeutics Inc.
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Steba Biotech S.A.
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
Aragon Pharmaceuticals, Inc.
ALpha-T
Hoffmann-La Roche
Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Revolution Medicines, Inc.
Evaluation of Length and Quality of Prostate Biopsies Taken by a New Biopsy Needle
Region Skane
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
STTELS
Seoul National University Bundang Hospital
PROfind
Advanced Accelerator Applications
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
Steba Biotech S.A.
PCM301
Steba Biotech S.A.
Protection of Rectum From High Radiation Doses Using a Spacer
University of Oulu
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
EMBARC-RF
Bioniche Life Sciences Inc.
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer
Lantheus Biosciences Ltd.
Study of WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
PCM304
Steba Biotech S.A.
NMIBC TURBT HG
UroGen Pharma Ltd.
Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
Arno Therapeutics
Study Using WST11 in Patients With Localized Prostate Cancer
Steba Biotech S.A.
SHTC-EUROPE-1
Medical Enterprises Europe B.V.
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
Medical Enterprises Europe B.V.